Biotech Values

[masterlongevity]

AMGN
I want to repost the most zealous quotes for those htat don't want to re-read the whole article...


1) The 4 products, "unambiguously have data that will support registration," Roger Perlmutter, Amgen's executive vice president of research and development, said at the Reuters Health Summit in New York.

2) AMG 706 is being studied in patients with gastrointestinal tumors who have become resistant to Gleevec. Perlmutter said the drug is "better than Avastin," because it inhibits all of the tumor growth receptors, rather than just the one that Avastin blocks.


3)The effects of denosumab "are really dramatic," Perlmutter said. The drug is given subcutaneously just once every six months and suppresses bone turnover in hours, he said.
"It's a flu shot for osteoporosis," Perlmutter said.